1-6 of 6
Tommi Salmi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL

Piers E.M. Patten, Arnon P. Kater, Jennifer A. Woyach, Jianyong Li, Talha Munir, Tommi Salmi, Patrick Phuong, Tian Tian, Mazyar Shadman
Journal: Blood
Blood (2024) 144 (Supplement 1): 3257.1.
https://doi.org/10.1182/blood-2024-198737
Published: 2024
Journal Articles

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Clinical Trials & Observations
Jennifer R. Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien, M.D., Constantine S. Tam, Lugui Qiu, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter Stephen Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Prof., Anders Osterborg, Habte A. Yimer, Megan (Der Yu) Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood blood.2024024667.
https://doi.org/10.1182/blood.2024024667
Published: 2024
Includes: Supplemental data
Journal Articles

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Jennifer R. Brown, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Luqui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda L. Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Megan (Der Yu) Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 202.
https://doi.org/10.1182/blood-2023-174289
Published: 2023
Journal Articles

Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study

Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Luqui Qiu, Vanitha Ramakrishnan, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1890.
https://doi.org/10.1182/blood-2023-173547
Published: 2023
Journal Articles

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiri Mayer, Amanda L. Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A. Yimer, Tommi Salmi, Megan (Der Yu) Wang, Lina Fu, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman
Journal: Blood
Blood (2022) 140 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2022-171538
Published: 2022
Journal Articles

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Peter Hillmen, MD PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O'Brien, MD, Lugui Qiu, MD PhD, Tommi Salmi, MD, James Hilger, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4307.
https://doi.org/10.1182/blood-2019-124213
Published: 2019